Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2024
Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
Badr Id Said, Yimin Geng, Shahed N Badiyan, et al.
JAMA Oncology
|
September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial
Robert Olson, Will Jiang, Mitchell Liu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 11, 2025
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial
Aiden Kooyman, Jee Suk Chang, Mitchell Liu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 12, 2020
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Umair Mahmood, Andrew Bang, Yu-Hui Chen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 23, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial
Reno Eufemon Cereno, Benjamin Mou, Sarah Baker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 15, 2026
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases
Robert Olson, Mitchell Liu, Alanah Bergman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 14, 2024
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial
Sarah Baker, Linden Lechner, Mitchell Liu, et al.
BMC Cancer
|
February 3, 2024
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET
Robert Olson, Hadassah Abraham, Curtis Leclerc, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2024
Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
Badr Id Said, Yimin Geng, Shahed N Badiyan, et al.
JAMA Oncology
|
September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial
Robert Olson, Will Jiang, Mitchell Liu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 11, 2025
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial
Aiden Kooyman, Jee Suk Chang, Mitchell Liu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 12, 2020
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Umair Mahmood, Andrew Bang, Yu-Hui Chen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 23, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial
Reno Eufemon Cereno, Benjamin Mou, Sarah Baker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 15, 2026
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases
Robert Olson, Mitchell Liu, Alanah Bergman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 14, 2024
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial
Sarah Baker, Linden Lechner, Mitchell Liu, et al.
BMC Cancer
|
February 3, 2024
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET
Robert Olson, Hadassah Abraham, Curtis Leclerc, et al.
Page
of 3